Data from the World Health Organization’s (WHO) Solidarity Trial shows that remdesivir does not help patients with severe COVID-19 symptoms get out of the hospital quickly. This result contradicts a National Institutes of Health (NIH)-funded trial which said that the drug reduced the amount of time of hospitalized adults to be discharged. Principal investigator for the NIH, Dr. Andre Kalil criticized the WHO study, saying that it lacked some of the basics which are critical to scientific research: “No data monitoring, no placebo, no double-blinding, no diagnostic confirmation of infection”.
Originally developed for Ebola, Remdesivir was granted an emergency use authorization by the Food and Drug Administration (FDA) after the results of the NIH study was released. The drug costs $3,120 for those with private insurance and $2,340 for patients covered by Medicaid 1.
Editor’s Note: It is striking that doctors are now quick to criticize the Solidarity Trial after remdesivir, the pharma doctor’s preferred COVID-19 medication, was proven to be ineffective. When doctors who swear by the efficacy of hydroxychloroquine raised the same concerns with the Solidarity Trial, same remdesivir-prescribing doctors were quick to dismiss the issue [see Hydroxychloroquine can dramatically ease the COVID-19 crisis]. Today, these anti-HCQ, pro-remdesivir doctors are silent.
Read Original Article
Massive WHO remdesivir study suggests no Covid-19 benefit. Doctors aren’t so sure.
Remdesivir, an antiviral drug, may be more beneficial when given earlier in the course of an infection.
Click the button below if you wish to read the article offline.